Accumulated other comprehensive income (loss)

9 Months Ended

Sep. 30, 2024

Accumulated other comprehensive income (loss)

NOTE 14 – Accumulated other comprehensive income (loss):

The components of, and changes within, accumulated other comprehensive income (loss) attributable to Teva are presented in the table below:

	Net Unrealized Gains (Losses)						Benefit Plans
	Foreign currency translation adjustments			Derivative financial instruments			Actuarial gains (losses) and prior service (costs) credits			Total
	(U.S. $ in millions)
Balance as of December 31, 2023, net of taxes	$	(2,384	)	$	(266	)	$	(46	)	$	(2,697	)
Other comprehensive income (loss) before reclassifications		(84	)		—			1			(83	)
Amounts reclassified to the statements of income		—			21			(3	)		18
Net other comprehensive income (loss) before tax		(84	)		21			(2	)		(65	)
Corresponding income tax		(7	)		—			—			(7	)
Net other comprehensive income (loss) after tax*		(91	)		21			(2	)		(72	)
Balance as of September 30, 2024, net of taxes	$	(2,475	)	$	(245	)	$	(48	)	$	(2,769	)

* Amounts do not include a $6 million loss from foreign currency translation adjustments attributable to non-controlling interests.

	Net Unrealized Gains (Losses)						Benefit Plans
	Foreign currency translation adjustments			Derivative financial instruments			Actuarial gains (losses) and prior service (costs) credits			Total
	(U.S. $ in millions)
Balance as of December 31, 2022, net of taxes	$	(2,514	)	$	(295	)	$	(28	)	$	(2,838	)
Other comprehensive income (loss) before reclassifications		(39	)		(5	)		—			(44	)
Amounts reclassified to the statements of income		—			24			(2	)		22
Net other comprehensive income (loss) before tax		(39	)		19			(2	)		(22	)
Corresponding income tax		(50	)		—			—			(50	)
Net other comprehensive income (loss) after tax*		(89	)		19			(2	)		(72	)
Balance as of September 30, 2023, net of taxes	$	(2,603	)	$	(276	)	$	(30	)	$	(2,910	)

* Amounts do not include a $84 million loss from foreign currency translation adjustments attributable to non-controlling interests.